Interview, Fireside Chat
Thrive Capital’s Dr. Nworah Ayogu on Why Neuralink Is More Interesting Than SpaceX
- Healthcare System Inefficiency: The U.S. spent approximately $40 trillion on healthcare over the last decade with zero net increase in life expectancy, which is currently dropping rather than rising.
- AI Adoption Rates: Two-thirds of physicians in America now use OpenAI, and OpenAI handles 300 million weekly healthcare-related queries, effectively positioning it as one of the largest healthcare providers in the U.S.
- Drug Discovery Timeline Goal: Isomorphic Labs aims to reduce drug discovery timelines from 10–15 years to four years, with a target success rate increase from 5% to 60–90%.
- Neuralink's "Bilingual" Talent Model: The company integrates world-class hardware engineers (ex-SpaceX/Tesla) with neurosurgeons and pathologists, insourcing pathology labs to ensure critical safety data is processed in-house.
- Fortel's Market Disruption: Founder Matt DeJong's hearing aid company designed custom chips at TSMC and utilized semantic noise processing to break the industry rating scale, achieving a 6/5 score compared to the previous 4.5 maximum.
- Merck's K-Truda Impact: A single drug, K-Truda (checkpoint inhibitor), is projected to generate $2025 revenue larger than the combined revenue of all other major pharmaceutical labs.
- Moderna/Merck Cancer Vaccine: A personalized mRNA vaccine combined with K-Truda showed a 50% reduction in melanoma recurrence over five years in Phase 3 trials.
- Lilly's Supply Chain Advantage: Eli Lilly leveraged superior manufacturing and commercialization capabilities to release GLP-1 drugs one year ahead of Novonordisk, directly contributing to its trillion-dollar valuation.
- OpenEvidence Adoption Speed: OpenEvidence reached usage by two-thirds of U.S. physicians in three years, outpacing the industry leader Epic, which took 40 years to reach less than 50% physician adoption.
- Cadence's Outcomes: Remote patient monitoring company Cadence reduced hospitalizations by 25% and increased controlled blood pressure rates by over 80% while saving Medicare $2.5 million weekly.
- N-of-1 Medicine Viability: A custom gene therapy for a rare genetic disease (Baby KJ) successfully cured a patient for $1.5 million, demonstrating the technical feasibility of personalized treatments despite cost barriers.
- Oscar Health Turnaround: Thrive's first healthcare investment, Oscar Health, recovered from a 95% drop in value (December 2022) to exceed its IPO price, driven by a decade-old modern tech stack and AI integration.
- Future Value Chain Expansion: Biotech firms are increasingly vertically integrating into care delivery and manufacturing to expand Total Addressable Market (TAM) and capture value beyond pure drug discovery.
- Workforce Shift: The speaker argues the U.S. requires a "10x nurse" more than a "10x engineer," citing the need for augmented clinical support rather than just increased software engineering capacity.
- Industry Spending Projection: U.S. healthcare spending is projected to rise from $5 trillion annually to $9 trillion by the end of the decade, with the sector expected to account for 30% of new jobs created.